A citation-based method for searching scientific literature

Richard S Finn, Baek-Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, Valeriy Breder, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L Chan, Jennifer Knox, Bruno Daniele, Scot W Ebbinghaus, Erluo Chen, Abby B Siegel, Andrew X Zhu, Ann-Lii Cheng. J Clin Oncol 2020
Times Cited: 535







List of co-cited articles
805 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Richard S Finn, Shukui Qin, Masafumi Ikeda, Peter R Galle, Michel Ducreux, Tae-You Kim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed O Kaseb,[...]. N Engl J Med 2020
69

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S Crocenzi, Masatoshi Kudo, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Jörg Trojan, Theodore H Welling,[...]. Lancet 2017
61

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Masatoshi Kudo, Richard S Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari Baron, Joong-Won Park, Guohong Han, Jacek Jassem,[...]. Lancet 2018
52

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X Zhu, Richard S Finn, Julien Edeline, Stephane Cattan, Sadahisa Ogasawara, Daniel Palmer, Chris Verslype, Vittorina Zagonel, Laetitia Fartoux, Arndt Vogel,[...]. Lancet Oncol 2018
51

Sorafenib in advanced hepatocellular carcinoma.
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner,[...]. N Engl J Med 2008
48

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Thomas Yau, Yoon-Koo Kang, Tae-You Kim, Anthony B El-Khoueiry, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming-Mo Hou, Ana Matilla,[...]. JAMA Oncol 2020
234
35

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder,[...]. Lancet 2017
33

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Andrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, Richard S Finn, Peter R Galle, Josep M Llovet, Eric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim,[...]. Lancet Oncol 2019
652
33

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Ghassan K Abou-Alfa, Tim Meyer, Ann-Lii Cheng, Anthony B El-Khoueiry, Lorenza Rimassa, Baek-Yeol Ryoo, Irfan Cicin, Philippe Merle, YenHsun Chen, Joong-Won Park,[...]. N Engl J Med 2018
925
30


Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
28

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Jun Suk Kim, Rongcheng Luo, Jifeng Feng, Shenglong Ye, Tsai-Sheng Yang,[...]. Lancet Oncol 2009
25

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Richard S Finn, Masafumi Ikeda, Andrew X Zhu, Max W Sung, Ari D Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko,[...]. J Clin Oncol 2020
237
24

NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, Olivier Govaere, Matthias Pinter, Marta Szydlowska, Revant Gupta, Mengjie Qiu, Aleksandra Deczkowska, Assaf Weiner,[...]. Nature 2021
144
19

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
17

Hepatocellular carcinoma.
Josep M Llovet, Robin Kate Kelley, Augusto Villanueva, Amit G Singal, Eli Pikarsky, Sasan Roayaie, Riccardo Lencioni, Kazuhiko Koike, Jessica Zucman-Rossi, Richard S Finn. Nat Rev Dis Primers 2021
431
16

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Michael S Lee, Baek-Yeol Ryoo, Chih-Hung Hsu, Kazushi Numata, Stacey Stein, Wendy Verret, Stephen P Hack, Jessica Spahn, Bo Liu, Heba Abdullah,[...]. Lancet Oncol 2020
155
15

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
Daniela Sia, Yang Jiao, Iris Martinez-Quetglas, Olga Kuchuk, Carlos Villacorta-Martin, Manuel Castro de Moura, Juan Putra, Genis Camprecios, Laia Bassaganyas, Nicholas Akers,[...]. Gastroenterology 2017
364
15

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.
Shukui Qin, Zhenggang Ren, Zhiqiang Meng, Zhendong Chen, Xiaoli Chai, Jianping Xiong, Yuxian Bai, Lin Yang, Hong Zhu, Weijia Fang,[...]. Lancet Oncol 2020
145
14

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.
Jorge A Marrero, Laura M Kulik, Claude B Sirlin, Andrew X Zhu, Richard S Finn, Michael M Abecassis, Lewis R Roberts, Julie K Heimbach. Hepatology 2018
14

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Riccardo Lencioni, Josep M Llovet. Semin Liver Dis 2010
14

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
Bruno Sangro, Ignacio Melero, Samir Wadhawan, Richard S Finn, Ghassan K Abou-Alfa, Ann-Lii Cheng, Thomas Yau, Junji Furuse, Joong-Won Park, Zachary Boyd,[...]. J Hepatol 2020
80
17

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Andrew X Zhu, Joon Oh Park, Baek-Yeol Ryoo, Chia-Jui Yen, Ronnie Poon, Davide Pastorelli, Jean-Frederic Blanc, Hyun Cheol Chung, Ari D Baron, Tulio Eduardo Flesch Pfiffer,[...]. Lancet Oncol 2015
492
13

Hepatocellular carcinoma.
Alejandro Forner, María Reig, Jordi Bruix. Lancet 2018
13

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
Austin G Duffy, Susanna V Ulahannan, Oxana Makorova-Rusher, Osama Rahma, Heiner Wedemeyer, Drew Pratt, Jeremy L Davis, Marybeth S Hughes, Theo Heller, Mei ElGindi,[...]. J Hepatol 2017
364
12

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Robin Kate Kelley, Bruno Sangro, William Harris, Masafumi Ikeda, Takuji Okusaka, Yoon-Koo Kang, Shukui Qin, David W-M Tai, Ho Yeong Lim, Thomas Yau,[...]. J Clin Oncol 2021
39
30

β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.
Marina Ruiz de Galarreta, Erin Bresnahan, Pedro Molina-Sánchez, Katherine E Lindblad, Barbara Maier, Daniela Sia, Marc Puigvehi, Verónica Miguela, María Casanova-Acebes, Maxime Dhainaut,[...]. Cancer Discov 2019
202
11

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
John D Gordan, Erin B Kennedy, Ghassan K Abou-Alfa, Muhammad Shaalan Beg, Steven T Brower, Terence P Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, William P Harris,[...]. J Clin Oncol 2020
96
11

Hepatocellular Carcinoma.
Augusto Villanueva. N Engl J Med 2019
11

Hepatocellular carcinoma.
Josep M Llovet, Jessica Zucman-Rossi, Eli Pikarsky, Bruno Sangro, Myron Schwartz, Morris Sherman, Gregory Gores. Nat Rev Dis Primers 2016
11

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
Bruno Sangro, Carlos Gomez-Martin, Manuel de la Mata, Mercedes Iñarrairaegui, Elena Garralda, Pilar Barrera, Jose Ignacio Riezu-Boj, Esther Larrea, Carlos Alfaro, Pablo Sarobe,[...]. J Hepatol 2013
562
10

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.
Jianming Xu, Jie Shen, Shanzhi Gu, Yun Zhang, Lihua Wu, Jian Wu, Guoliang Shao, Yanqiao Zhang, Li Xu, Tao Yin,[...]. Clin Cancer Res 2021
65
15

Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
Ann-Lii Cheng, Chiun Hsu, Stephen L Chan, Su-Pin Choo, Masatoshi Kudo. J Hepatol 2020
111
9


Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, Gar-Yang Chau, Jiamei Yang, Masatoshi Kudo, Jianqiang Cai, Ronnie T Poon, Kwang-Hyub Han, Won Young Tak,[...]. Lancet Oncol 2015
510
9

A global view of hepatocellular carcinoma: trends, risk, prevention and management.
Ju Dong Yang, Pierre Hainaut, Gregory J Gores, Amina Amadou, Amelie Plymoth, Lewis R Roberts. Nat Rev Gastroenterol Hepatol 2019
9

AASLD guidelines for the treatment of hepatocellular carcinoma.
Julie K Heimbach, Laura M Kulik, Richard S Finn, Claude B Sirlin, Michael M Abecassis, Lewis R Roberts, Andrew X Zhu, M Hassan Murad, Jorge A Marrero. Hepatology 2018
9

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Zhenggang Ren, Jianming Xu, Yuxian Bai, Aibing Xu, Shundong Cang, Chengyou Du, Qiu Li, Yinying Lu, Yajin Chen, Yabing Guo,[...]. Lancet Oncol 2021
42
21

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Nobukazu Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino,[...]. Gut 2020
147
9

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.
James J Harding, Subhiksha Nandakumar, Joshua Armenia, Danny N Khalil, Melanie Albano, Michele Ly, Jinru Shia, Jaclyn F Hechtman, Ritika Kundra, Imane El Dika,[...]. Clin Cancer Res 2019
207
8

Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.
Tobias Flecken, Nathalie Schmidt, Sandra Hild, Emma Gostick, Oliver Drognitz, Robert Zeiser, Peter Schemmer, Helge Bruns, Thomas Eiermann, David A Price,[...]. Hepatology 2014
209
8


Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).
Jian Zhou, Huichuan Sun, Zheng Wang, Wenming Cong, Jianhua Wang, Mengsu Zeng, Weiping Zhou, Ping Bie, Lianxin Liu, Tianfu Wen,[...]. Liver Cancer 2020
90
8

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
8

Systemic treatment of hepatocellular carcinoma: An EASL position paper.
Jordi Bruix, Stephen L Chan, Peter R Galle, Lorenza Rimassa, Bruno Sangro. J Hepatol 2021
35
22

Advances in immunotherapy for hepatocellular carcinoma.
Bruno Sangro, Pablo Sarobe, Sandra Hervás-Stubbs, Ignacio Melero. Nat Rev Gastroenterol Hepatol 2021
81
9

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
Tim Meyer, Richard Fox, Yuk Ting Ma, Paul J Ross, Martin W James, Richard Sturgess, Clive Stubbs, Deborah D Stocken, Lucy Wall, Anthony Watkinson,[...]. Lancet Gastroenterol Hepatol 2017
213
8

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Thomas Yau, Joong-Won Park, Richard S Finn, Ann-Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J Harding, Philippe Merle, Olivier Rosmorduc,[...]. Lancet Oncol 2022
13
61

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.
Kornelius Schulze, Sandrine Imbeaud, Eric Letouzé, Ludmil B Alexandrov, Julien Calderaro, Sandra Rebouissou, Gabrielle Couchy, Clément Meiller, Jayendra Shinde, Frederic Soysouvanh,[...]. Nat Genet 2015
875
8

Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).
Philipp K Haber, Marc Puigvehí, Florian Castet, Vennis Lourdusamy, Robert Montal, Parissa Tabrizian, Michael Buckstein, Edward Kim, Augusto Villanueva, Myron Schwartz,[...]. Gastroenterology 2021
19
36


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.